IL2 and renal cell carcinoma: Treatment using IL-2 alone, IFN-α alone, or IL-2 in combination with IFN-α achieved objective response rates (RRs) between 15% and 31% in stage IV RCC.11–14 These results formed the basis for several adjuvant clinical trials with immune therapies in RCC.